AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

AbbVie is now pushing Skyrizi and Rinvoq to counter the drop in Humira sales and has forecast the two newer drugs to generate ...

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...

Adjusted earnings guidance was also lifted to a range of $12.09 to $12.29. Immunology drugs Skyrizi and Rinvoq generated $5.1 ...